Clinical Trial Update: Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating TissueGene-C (TG-C) for Kellgren/Lawrence grade 2-3 knee osteoarthritis is ongoing. The study status is ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• TissueGene-C (TG-C)

Snippet

Sponsor: Kolon TissueGene, Inc. | Conditions: Degenerative Osteoarthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING